ES2169986A1 - Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral. - Google Patents

Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.

Info

Publication number
ES2169986A1
ES2169986A1 ES200000610A ES200000610A ES2169986A1 ES 2169986 A1 ES2169986 A1 ES 2169986A1 ES 200000610 A ES200000610 A ES 200000610A ES 200000610 A ES200000610 A ES 200000610A ES 2169986 A1 ES2169986 A1 ES 2169986A1
Authority
ES
Spain
Prior art keywords
cdp
choline
prophylactic treatment
cerebral ischemia
suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200000610A
Other languages
English (en)
Other versions
ES2169986B1 (es
Inventor
Ambros Rafael Foguet
Massana Jorge Ramentol
Abizanda Isidro Jose Ferrer
Fernandez De Pinedo Raf Lozano
Ruiz Julio Jose Secades
Carreno Manuel Mauricio Raga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEALTH TECH BIO ACTIVES, S.L.U.
Original Assignee
Ferrer Internacional SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200000610A priority Critical patent/ES2169986B1/es
Application filed by Ferrer Internacional SA filed Critical Ferrer Internacional SA
Priority to AU2001248346A priority patent/AU2001248346B2/en
Priority to PCT/EP2001/002825 priority patent/WO2001068064A2/en
Priority to CZ20023095A priority patent/CZ300616B6/cs
Priority to CA002402668A priority patent/CA2402668C/en
Priority to BR0109155-7A priority patent/BR0109155A/pt
Priority to DE60116478T priority patent/DE60116478T2/de
Priority to PT01921332T priority patent/PT1265621E/pt
Priority to AU4834601A priority patent/AU4834601A/xx
Priority to KR1020027012086A priority patent/KR100883279B1/ko
Priority to NZ520824A priority patent/NZ520824A/en
Priority to AT01921332T priority patent/ATE314855T1/de
Priority to IL15116501A priority patent/IL151165A0/xx
Priority to EP01921332A priority patent/EP1265621B1/en
Priority to DK01921332T priority patent/DK1265621T3/da
Priority to US10/221,581 priority patent/US6930096B2/en
Priority to MXPA02008917A priority patent/MXPA02008917A/es
Priority to PL358249A priority patent/PL199383B1/pl
Priority to JP2001566628A priority patent/JP4920849B2/ja
Priority to RU2002127783/15A priority patent/RU2255741C2/ru
Publication of ES2169986A1 publication Critical patent/ES2169986A1/es
Priority to ZA200206348A priority patent/ZA200206348B/en
Priority to IL151165A priority patent/IL151165A/en
Priority to NO20024399A priority patent/NO330163B1/no
Publication of ES2169986B1 publication Critical patent/ES2169986B1/es
Application granted granted Critical
Priority to US11/133,251 priority patent/US7635691B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de CDP-Colina para el tratamiento profiláctico de la isquemia cerebral. La invención describe el tratamiento profiláctico de la isquemia cerebral con CDP-Colina en pacientes que han sufrido cirugía mayor o se encuentran en alto riesgo de sufrir un accidente isquémico agudo.
ES200000610A 2000-03-14 2000-03-14 Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral. Expired - Fee Related ES2169986B1 (es)

Priority Applications (24)

Application Number Priority Date Filing Date Title
ES200000610A ES2169986B1 (es) 2000-03-14 2000-03-14 Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
DK01921332T DK1265621T3 (da) 2000-03-14 2001-03-13 Anvendelse af CDP-cholin til profylaktisk behandling af cerebral iskæmi
CZ20023095A CZ300616B6 (cs) 2000-03-14 2001-03-13 Farmaceutický prostredek
CA002402668A CA2402668C (en) 2000-03-14 2001-03-13 Use of cdp-choline for the prophylactic treatment of cerebral ischemia
BR0109155-7A BR0109155A (pt) 2000-03-14 2001-03-13 Uso de cdp-colina para o tratamento profilático de isquemia cerebral
DE60116478T DE60116478T2 (de) 2000-03-14 2001-03-13 Verwendung von cdp-cholin zur prophylaxe der cerebralen ischämie
PT01921332T PT1265621E (pt) 2000-03-14 2001-03-13 Utilizacao da cdp-colina para o tratamento profilactico da isquemia cerebral
AU4834601A AU4834601A (en) 2000-03-14 2001-03-13 Use of cdp-choline for the prophylactic treatment of cerebral ischemia
KR1020027012086A KR100883279B1 (ko) 2000-03-14 2001-03-13 씨디피-콜린 또는 그의 약학적으로 수용가능한 염을 포함하는 뇌 허혈 예방용 약학 조성물
NZ520824A NZ520824A (en) 2000-03-14 2001-03-13 Use of CDP-choline for before the onset of a cerebral ischemic episode
AT01921332T ATE314855T1 (de) 2000-03-14 2001-03-13 Verwendung von cdp-cholin zur prophylaxe der cerebralen ischämie
IL15116501A IL151165A0 (en) 2000-03-14 2001-03-13 Use of cdp-choline for the prophylactic treatment of cerebral ischemia
AU2001248346A AU2001248346B2 (en) 2000-03-14 2001-03-13 Use of cdp-choline for the prophylactic treatment of cerebral ischemia
EP01921332A EP1265621B1 (en) 2000-03-14 2001-03-13 Use of cdp-choline for the prophylactic treatment of cerebral ischemia
RU2002127783/15A RU2255741C2 (ru) 2000-03-14 2001-03-13 Cdp-холин - профилактическое средство для лечения церебральной ишемии и способ лечения с его использованием
MXPA02008917A MXPA02008917A (es) 2000-03-14 2001-03-13 Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
PL358249A PL199383B1 (pl) 2000-03-14 2001-03-13 Zastosowanie CDP-choliny w leczeniu profilaktycznym niedokrwienia mózgu
JP2001566628A JP4920849B2 (ja) 2000-03-14 2001-03-13 脳虚血の予防的治療のためのｃｄｐ−コリンの使用
US10/221,581 US6930096B2 (en) 2000-03-14 2001-03-13 Use of CDP-choline for the prophylactic treatment of cerebral ischemia
PCT/EP2001/002825 WO2001068064A2 (en) 2000-03-14 2001-03-13 Use of cdp-choline for the prophylactic treatment of cerebral ischemia
ZA200206348A ZA200206348B (en) 2000-03-14 2002-08-08 Use of CDP-Choline for the prophylactic treatment of cerebral ischemia.
IL151165A IL151165A (en) 2000-03-14 2002-08-09 Use of citidine diphosphate choline for the preparation of a drug for the treatment of cerebral ischemic disease
NO20024399A NO330163B1 (no) 2000-03-14 2002-09-13 Anvendelse av CDP kolin eller et farmasoytisk akseptabelt salt derav for fremstilling av et medikament for profylaktisk behandling av cerebral iskemi
US11/133,251 US7635691B2 (en) 2000-03-14 2005-05-20 Use of CDP-choline for the prophylactic treatment of cerebral ischemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200000610A ES2169986B1 (es) 2000-03-14 2000-03-14 Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.

Publications (2)

Publication Number Publication Date
ES2169986A1 true ES2169986A1 (es) 2002-07-16
ES2169986B1 ES2169986B1 (es) 2003-06-16

Family

ID=8492692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200000610A Expired - Fee Related ES2169986B1 (es) 2000-03-14 2000-03-14 Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.

Country Status (21)

Country Link
US (2) US6930096B2 (es)
EP (1) EP1265621B1 (es)
JP (1) JP4920849B2 (es)
KR (1) KR100883279B1 (es)
AT (1) ATE314855T1 (es)
AU (2) AU2001248346B2 (es)
BR (1) BR0109155A (es)
CA (1) CA2402668C (es)
CZ (1) CZ300616B6 (es)
DE (1) DE60116478T2 (es)
DK (1) DK1265621T3 (es)
ES (1) ES2169986B1 (es)
IL (2) IL151165A0 (es)
MX (1) MXPA02008917A (es)
NO (1) NO330163B1 (es)
NZ (1) NZ520824A (es)
PL (1) PL199383B1 (es)
PT (1) PT1265621E (es)
RU (1) RU2255741C2 (es)
WO (1) WO2001068064A2 (es)
ZA (1) ZA200206348B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169986B1 (es) * 2000-03-14 2003-06-16 Ferrer Int Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
CN1605336A (zh) * 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
RU2519228C1 (ru) * 2013-02-12 2014-06-10 Клиника государственного бюджетного образовательного учреждения высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ предупреждения ишемии головного мозга при реконструктивных операциях на прецеребральных сосудах
WO2021048871A1 (en) 2019-09-15 2021-03-18 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for treating neurological disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2724825B2 (ja) * 1987-06-15 1998-03-09 旭化成工業株式会社 シチジンジリン酸コリンの製造方法
JP3018823B2 (ja) * 1993-03-11 2000-03-13 キヤノン株式会社 非循環式シート材搬送装置
JPH11511732A (ja) * 1995-03-06 1999-10-12 インターニューロン ファーマシューティカルズ，インコーポレーテッド シチコリンを用いる梗塞容積の低減
US5872108A (en) * 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
CN1122241A (zh) * 1995-09-18 1996-05-15 牛俊江 脑脉通注射液
ES2169986B1 (es) * 2000-03-14 2003-06-16 Ferrer Int Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRICOURT M.-O. et al.: "AmÉlioration par la CDP-choline de la rÉcupÉration post-opÉratoire de sujets à risque cÉrÉbral", 1990, Agressologie, Vol. 31 (7), paginas 457-463. Todo el documento. *
BRUHWYLER J. et al.: "Multicentric open-label study of the efficacy and tolerability of citicoline in the treatment of acute cerebral infarction", 1997, Current Therapeutic Res., Vol. 58 (5), paginas 309-316. Todo el documento. *
TAZAKY Y. et al.: "Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study", 1988, Stroke, Vol. 19 (2), paginas 211-216, ISSN: 0039-2499. Todo el documento. *
TORNOS M.E. et al.: "Pharmacological study of CDP-choline", 1983, Arzneim.-Forsch./Drug Res., Vol. 33 (7A), paginas 1022-1024. Todo el documento. *

Also Published As

Publication number Publication date
EP1265621A2 (en) 2002-12-18
ATE314855T1 (de) 2006-02-15
DE60116478T2 (de) 2006-09-07
US6930096B2 (en) 2005-08-16
US20030050284A1 (en) 2003-03-13
ES2169986B1 (es) 2003-06-16
KR20030005225A (ko) 2003-01-17
IL151165A0 (en) 2003-04-10
PL199383B1 (pl) 2008-09-30
ZA200206348B (en) 2003-08-20
NZ520824A (en) 2004-04-30
DK1265621T3 (da) 2006-05-08
AU4834601A (en) 2001-09-24
RU2002127783A (ru) 2004-03-27
NO330163B1 (no) 2011-02-28
PT1265621E (pt) 2006-05-31
JP4920849B2 (ja) 2012-04-18
RU2255741C2 (ru) 2005-07-10
WO2001068064A3 (en) 2002-01-17
US20050222077A1 (en) 2005-10-06
CA2402668C (en) 2008-01-08
NO20024399L (no) 2002-09-13
MXPA02008917A (es) 2003-02-12
IL151165A (en) 2009-06-15
AU2001248346B2 (en) 2005-03-10
JP2003526657A (ja) 2003-09-09
CZ20023095A3 (cs) 2003-02-12
WO2001068064A2 (en) 2001-09-20
EP1265621B1 (en) 2006-01-04
PL358249A1 (en) 2004-08-09
US7635691B2 (en) 2009-12-22
DE60116478D1 (de) 2006-03-30
NO20024399D0 (no) 2002-09-13
KR100883279B1 (ko) 2009-02-11
CZ300616B6 (cs) 2009-07-01
CA2402668A1 (en) 2001-09-20
BR0109155A (pt) 2003-04-22

Similar Documents

Publication Publication Date Title
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
MXPA04001524A (es) 29-enoles de rapamicina.
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
HK1069767A1 (en) Methods for inhibiting ocular processes
PL1656372T3 (pl) Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
MXPA04001523A (es) Dialdehidos de rapamicina.
EP1381280A4 (en) VIRAL VECTORS AND USE THEREOF IN THERAPEUTIC METHODS
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
EP1409015A4 (en) METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS
AU2002358199A1 (en) Shorts or underpants retaining the sexual organs
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
ES2169986A1 (es) Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
AU4259299A (en) New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
IL143280A0 (en) Use of riluzole for treating acoustic traumas
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU4643501A (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
AU2001248346A1 (en) Use of CDP-choline for the prophylactic treatment of cerebral ischemia
NZ514691A (en) Method to type prion proteins
WO2001070093A3 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
AU2002254524A1 (en) Use of semenogelin in the diagnosis, prognosis and treatment of cancer
WO2001049298A3 (fr) Nouvelle application therapeutique de l"enoxaparine

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020716

Kind code of ref document: A1

Effective date: 20020716

FG2A Definitive protection

Ref document number: 2169986B1

Country of ref document: ES

PC2A Transfer of patent

Owner name: HEALTH TECH BIO ACTIVES, S.L.U.

Effective date: 20191204

FD2A Announcement of lapse in spain

Effective date: 20200626